FP

Fosun Pharma

Australia - Sydney
Diagnostics
WebsiteLinkedInCareers Page

Focus: Small molecules, diagnostics, traditional

Fosun Pharma is a life sciences company focused on Small molecules, diagnostics, traditional.

OncologyNeurologyCardiovascularInfectious DiseasesRespiratory
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (18)

32 discontinued products not shown

ALBUTEROL SULFATE
albuterol sulfate
Post-LOE
INHALATION · SOLUTION
CLINICAL PHARMACOLOGY The prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular responses. In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors in bronchial smooth muscle, 10% to 50% of the beta-receptors in the human heart may be beta 2 -receptors. The precise function of these receptors, however, is not yet established. Albuterol has been shown in most controlled clinical trials to have more effect on the respiratory tract in the form of bronchial smooth muscle relaxation than isoproterenol at comparable doses while producing fewer cardiovascular effects. Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes. Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol-O-methyl transferase. Studies in asthmatic patients have shown that less than 20% of a single albuterol dose was absorbed following IPPB (intermittent positive-pressure breathing) or nebulizer administration; the remaining amount was recovered from the nebulizer and apparatus and expired air. Most of the absorbed dose was recovered in the urine 24 hours after drug administration. Following a 3 mg dose of nebulized albuterol, the maximum albuterol plasma level at 0.5 hour was 2.1 ng/mL (range 1.4 to 3.2 ng/mL). There was a significant dose-related response in FEV 1 (forced expiratory volume in one second) and peak flow rate. It has been demonstrated that following oral administration of 4 mg albuterol, the elimination half-life was five to six hours. Animal studies show that albuterol does not pass the blood-brain barrier. Recent studies in laboratory animals (minipigs, rodents, and dogs) recorded the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines were administered concurrently. The significance of these findings when applied to humans is currently unknown. In controlled clinical trials, most patients exhibited an onset of improvement in pulmonary function within 5 minutes as determined by FEV 1 . FEV 1 measurements also showed that the maximum average improvement in pulmonary function usually occurred at approximately 1 hour following inhalation of 2.5 mg of albuterol by compressor- nebulizer, and remained close to peak for 2 hours. Cl
2017
30
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
ipratropium bromide and albuterol sulfate
Post-LOE
INHALATION · SOLUTION
CLINICAL PHARMACOLOGY Ipratropium bromide and albuterol sulfate inhalation solution is a combination of the β2-adrenergic bronchodilator, albuterol sulfate, and the anticholinergic bronchodilator, ipratropium bromide. Albuterol Sulfate Mechanism of Action : The prime action of β-adrenergic drugs is to stimulate adenyl cyclase, the enzyme that catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). The cAMP thus formed mediates the cellular responses. In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on β2-adrenergic receptors compared with isoproterenol. While it is recognized that β2-adrenergic receptors are the predominant receptors in bronchial smooth muscle, recent data indicated that 10% to 50% of the β-­receptors in the human heart may be β2-receptors. The precise function of these receptors, however, is not yet established. Albuterol has been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects. Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other β-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients. Pharmacokinetics: Albuterol sulfate is longer acting than isoproterenol in most patients by any route of administration, because it is not a substrate for the cellular uptake processes for catecholamine nor for the metabolism of catechol-O-methyl transferase. Instead the drug is conjugatively metabolized to albuterol 4'-O-sulfate. Animal Pharmacology/Toxicology: Intravenous studies in rats with albuterol sulfate have demonstrated that albuterol crosses the blood-brain barrier and reaches brain concentrations amounting to approximately 5% of plasma concentrations. In structures outside of the blood-brain barrier (pineal and pituitary glands), albuterol concentrations were found to be 100 times those found in whole brain. Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrythmias and sudden death (with histological evidence of myocardial necrosis) when beta-agonists and methyl-xanthines are administered concurrently. The clinical significance of these findings is unknown. Ipratropium Bromide Mechanism of Action:. Ipratropium bromide is an anticholinergic (parasympatholytic) agent, which blocks the muscarinic receptors of acetylcholine, and, based on animal studies, appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the increases in intracellular concentration of cyclic guanosine monophosphate (cGMP), resulting from the interaction of acetylcholine with the muscarinic receptors of bronchial smooth muscle. Pharmaco
bronchospasm associated with COPD in patients requiring more than one bronchodilatorCOPD
2017
30
ALENDRONATE SODIUM
alendronate sodium
Post-LOE
ORAL · TABLET
action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined 6 and 49 days after [H]alendronate administration in rats and mice, respectively, showed that normal bone was formed on top of the alendronate, which was incorporated inside the matrix. While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover (i.e., the number of sites at which bone is remodeled). In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass.
osteoporosis in postmenopausal womenglucocorticoid-induced osteoporosis in menwomen receiving glucocorticoids in a daily dosage equivalent to 7+6 more
2008
30
AMBRISENTAN
ambrisentan
Post-LOE
ORAL · TABLET
Endothelin Receptor Antagonists
pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise abilitydelay clinical worseninghypertension
2019
30
ARFORMOTEROL TARTRATE
arformoterol tartrate
Post-LOE
INHALATION · SOLUTION
Arformoterol, the (R,R)-enantiomer of formoterol, is a selective long-acting beta 2 -adrenergic receptor agonist (beta 2 -agonist) that has two-fold greater potency than racemic formoterol (which contains both the (S,S) and (R,R)-enantiomers). The (S,S)-enantiomer is about 1,000-fold less potent as a beta 2 -agonist than the (R,R)-enantiomer. While it is recognized that beta 2 -receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -receptors are the predominant receptors in the heart, data indicate that there are also beta 2 -receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta 2 -agonists may have cardiac effects. The pharmacologic effects of beta 2 -adrenoceptor agonist drugs, including arformoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased intracellular cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Arformoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness. The relevance of these in vitro and animal findings to humans is unknown.
acute deteriorations of chronic obstructive pulmonary diseaseasthmachronic obstructive pulmonary disease+1 more
2022
30
BICALUTAMIDE
bicalutamide
Post-LOE
ORAL · TABLET
Androgen Receptor Antagonists
2009
30
BOSENTAN
bosentan
Post-LOE
ORAL · TABLET
. Bosentan has a slightly higher affinity for ET A receptors than for ET B receptors. The clinical impact of dual endothelin blockage is unknown. Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ET A and ET B receptors in the endothelium and vascular smooth muscle. ET-1 concentrations are elevated in plasma and lung tissue of patients with PAH, suggesting a pathogenic role for ET-1 in this disease.
pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise abilityto decrease clinical worseninghypertension
2019
30
BROMSITE
bromfenac
Peak
OPHTHALMIC · SOLUTION/DROPS
anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
postoperative inflammationprevention of ocular pain in patients undergoing cataract surgery
2016
8
BUDESONIDE
budesonide
Post-LOE
INHALATION · SUSPENSION
Corticosteroid Hormone Receptor Agonists
asthma
2021
30
BUPRENORPHINE HYDROCHLORIDE
buprenorphine
Post-LOE
SUBLINGUAL · TABLET
buprenorphine, a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor.
opioid dependence
2016
30
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
buprenorphine and naloxone
Post-LOE
SUBLINGUAL · TABLET
naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
2016
30
BYNFEZIA PEN
octreotide acetate
Growth
PeptideSUBCUTANEOUS · SOLUTION
(octreotide acetate) exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin releasing hormone (GnRH), decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, VIP, secretin, motilin, and pancreatic polypeptide. By virtue of these pharmacological actions, octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and VIP secreting adenomas (watery diarrhea).
blood levels of growth hormone (GH)insulin gro wth factor-1 (I GF-1insulin gro wth factor-1 (I GF-1; somatomedin C) in acromegaly patients+2 more
2024
0
View all 18 products

Pipeline & Clinical Trials

Azvudine
COVID-19
N/A
Clinical Trials (1)
NCT05675748Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients
N/A
ultrasonic cardiography
Mitral Regurgitation
N/A
Clinical Trials (1)
NCT06162780TEER for Severe DMR of Low to Intermediate Surgery Risk
N/A
Ion Endoluminal System
Pulmonary Nodule, Solitary
N/A
Clinical Trials (1)
NCT06308120A Trial to Compare Robotic Assisted Bronchoscopy Ion's Clinical Utility for Peripheral Lung Nodule Access and Diagnosis to ENB
N/A
Phase 1
Clinical Trials (1)
NCT03944499Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
Phase 1
BNT162b1
SARS-CoV-2
Phase 1
Clinical Trials (1)
NCT04523571Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects
Phase 1
FCN-159
Melanoma
Phase 1
Clinical Trials (1)
NCT03932253MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Phase 1
Phase 1
Clinical Trials (1)
NCT03690154A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
Phase 1
Phase 1
Clinical Trials (1)
NCT07345637Phase I Study of FXS887 in the Treatment of Solid Tumors
Phase 1
Phase 1/2
Clinical Trials (1)
NCT05154201Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.
Phase 1/2
Luvometinib Tablets
Neurofibromatosis 1
Phase 1/2
Clinical Trials (1)
NCT07024394Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04954001Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04237805A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
Phase 1/2
Argesun 60mg
Severe Malaria
Phase 2
Clinical Trials (1)
NCT05140278Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate
Phase 2
Phase 2
Clinical Trials (1)
NCT06913725An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations
Phase 2
BNT162b2
SARS-CoV-2
Phase 2
Clinical Trials (1)
NCT04649021Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
Phase 2
FCN-338 + Azacitidine
Safety
Phase 2
Clinical Trials (1)
NCT06858618FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms
Phase 2
Azvudine
COVID-19
Phase 2
Clinical Trials (1)
NCT05682599Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China
Phase 2
Avatrombopag
Anemia, Aplastic
Phase 2
Clinical Trials (1)
NCT06254287Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA
Phase 2
Phase 2
Clinical Trials (1)
NCT05997602To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
Phase 2
Phase 2/3
Clinical Trials (1)
NCT05633433Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19
Phase 2/3
13-valent pneumococcal conjugate vaccine
Streptococcus Pneumoniae Infection
Phase 3
Clinical Trials (1)
NCT05759520Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
Phase 3
Luvometinib
Low-grade Glioma
Phase 3
Clinical Trials (1)
NCT07004075FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration
Phase 3
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection
Breast Cancer
Phase 3
Clinical Trials (1)
NCT05755048FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Phase 3
Phase 3
Clinical Trials (1)
NCT04743739Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN
Phase 3
Phase 3
Clinical Trials (1)
NCT05913037FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Phase 3
Drug: Foritinib Succinate
Non-Small Cell Lung Cancer
Phase 3
Clinical Trials (1)
NCT06569420Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 1994
Portfolio: 210 approved products, 26 clinical trials
Top TAs: Oncology, Neurology, Cardiovascular
Portfolio Health
Pre-Launch1 (0%)
Growth1 (0%)
Peak13 (6%)
LOE Approaching9 (4%)
Post-LOE186 (89%)
210 total products
Therapeutic Area Focus
Oncology
15 marketed9 pipeline
Neurology
22 marketed
Cardiovascular
18 marketed
Immunology
7 marketed
Endocrinology
6 marketed
Infectious Diseases
5 marketed1 pipeline
Marketed
Pipeline